

해외 바이오의약품 임상 현황 ('23년 6월 1주)

한국바이오의약품협회, 2023.06.13.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

- 모니터링 기간: 2023.06.05.~2023.06.11.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 4건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05672316	Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy	Biological: Balstilimab Procedure: Biospecimen Collection Biological: Botensilimab Procedure: Computed Tomography Drug: Regorafenib	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05672316
NCT05626322	Effects of Maplirpacept (PF-07901801), Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Drug: Maplirpacept Drug: Tafasitamab Drug: Lenalidomide	Pfizer MorphoSys AG Incyte Corporation	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05626322
NCT05709821	IMM60 and Pembrolizumab in Melanoma and NSCLC	Drug: IMM60 Drug: Pembrolizumab	iOx Therapeutics Merck Sharp & Dohme LLC Portage Biotech	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05709821
NCT05874713	Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults	Biological: aH5N8c on Day 1 Biological: aH5N6c on Day 1 Biological: aH5N8c on Day 22 Biological: aH5N6c on Day 22 Biological: aH5N8c on Day 202	Seqirus Department of Health and Human Services	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05874713

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05709821	IMM60 and Pembrolizumab in Melanoma and NSCLC	Drug: IMM60 Drug: Pembrolizumab	iOx Therapeutics Merck Sharp & Dohme LLC Portage Biotech	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05709821

○ 중국 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05890742	A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer	Drug: IBI310 Procedure: Radical surgery Drug: Sintilimab	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05890742
NCT05883852	EC-THP Versus TcbHP in HER2-positive Lymph Node Positive Early Breast Cancer	Drug: Docetaxel Drug: carboplatin Drug: Trastuzumab Drug: Pertuzumab Drug: Epirubicin Drug: cyclophosphamide	Fudan University	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05883852
NCT05896774	A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China	Drug: Maplirpacept	Pfizer	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05896774

○ 일본 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05626322	Effects of Maplirpacept (PF-07901801), Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Drug: Maplirpacept Drug: Tafasitamab Drug: Lenalidomide	Pfizer MorphoSys AG Incyte Corporation	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05626322